Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized Neoantigen Peptides in EGFR Mutant NSCLC
NCT04397926Phase 1Unknown
- Sponsor
- Sun Yat-sen University
- Start
- May 2020
- Primary completion
- May 2022
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HJ-N-001 in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Primary endpoint: Safety of the neoantigen vaccine treatment at 24 months. Status: unknown.
02
Drugs
HJ-N-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04397926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04397926.